Benefit of rebiopsy for deciding treatment strategy in rectal cancer: A case report

Kenta Kawasaki, Yasuo Hamamoto, Takeshi Suzuki, Kenro Hirata, Yasutaka Sukawa, Akiyoshi Kasuga, Yuichiro Hayashi, Hiromasa Takaishi, Kaori Kameyama, Takanori Kanai

Research output: Contribution to journalArticlepeer-review

2 Citations (Scopus)


Rebiopsy is considered an option for specific types of cancer, such as breast, non-small cell lung, and prostate cancer, in clinical trials and in practice. The benefit of rebiopsy comes from the selection of a new treatment strategy based on the genetic profile of the cells, which may reflect the development of drug resistance or hormonal changes. For colorectal cancer, the presence of different genomic mutations between the primary tumor and its metastases is rare, and rebiopsy is therefore not generally performed. The present study reports the case of a 68-year-old man who was initially diagnosed with metastatic adenocarcinoma from a primary colorectal cancer, but was subsequently rediagnosed with metastatic neuroendocrine carcinoma based on the pathological rebiopsy results. The patient responded well to cisplatin and etoposide treatment, after not responding to initial FOLFOX treatment. In this case, rebiopsy resulted in a change in treatment regimen and improved the patient's quality of life and his long-term survival. This case indicates that, when a colorectal cancer patient is unresponsive to standard treatment, it may be beneficial for the clinician to suspect an atypical histological type, and to consider rebiopsy.

Original languageEnglish
Pages (from-to)3697-3700
Number of pages4
JournalOncology Letters
Issue number3
Publication statusPublished - 2017


  • Biopsy
  • Colorectal cancer
  • Neuroendocrine cancer

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Benefit of rebiopsy for deciding treatment strategy in rectal cancer: A case report'. Together they form a unique fingerprint.

Cite this